15207-93-9

Upstream product

• 100-44-7 benzyl chloride 
• 94-52-0 5-nitrobenzimidazole 
• 369-36-8 6-fluoro-3-nitroaniline 
• 100-46-9 benzylamine 
• 100-39-0 benzyl bromide 

Downstream Products

• 1250258-15-1 (Z)-2-{9-benzyl-6-nitro-2,2-dimethyl-9,9a-dihydro[1,3]oxazolo[3,2-a]benzimidazol-3(2H)-yliden}acetonitrile 
• 1169393-04-7 6-benzyl-9-nitrobenzo[4,5]imidazo[2,1-b]quinazolin-12(6H)-one 
• 1234801-41-2 (2-{[(4E)-2-amino-1-oxaspiro[4.5]dec-2-en-4-ylidene]amino}-4-nitrophenyl)benzylformamide 
• 1234801-40-1 (2-{[(3E)-5-amino-2,2-dimethylfuran-3(2H)-ylidene]amino}-4-nitrophenyl)benzylformamide 
• 1007871-92-2 2-(1-benzyl-5-nitro-1H-benzo[d]imidazol-4-yl)acetonitrile 
• 27978-94-5 N³-benzyl-5-nitrobenzimidazole 

Relevant academic research and scientific papers

C–N bond formation and cyclization: A straightforward and metal-free synthesis of N-1-alkyl-2-unsubstituted benzimidazoles

A straightforward and metal-free synthesis of N-1-alkyl-2-unsubstituted benzimidazoles from the corresponding o-fluoro aryl formamidines and primary amines using microwave irradiation is described. The displacement of -F by the primary amine and cyclizati

New Fluorescent Nickel(II) Complexes as a Catalyst for Biodiesel Formation: Synthesis, Structure, Spectral Properties, and DFT Calculations

Abstract: Two fluorescent heterocyclic ligands were obtained by reduction ofimidazo[4,5-e][2,1]benzoxazolederivatives with Fe/HCl. New fluorescent nickel(II) complexes were synthesizedby coordination of Ni(II) cation with the heterocyclic ligands. The structure ofthe complexes was established by spectral and analytical data, Job plot, and DFTcalculations. Photophysical properties of Ni(II) complexes were characterized byUV-Vis and fluorescence spectroscopy. The optimized geometry, spectralproperties, and energy difference between the HOMO and LUMO frontier orbitals ofthe ligands and Ni(II) complexes were obtained by DFT calculations at theB3LYP/6-311++G(d,p) level. The calculated spectral properties are in goodagreement with the experimental values. The complexes were also tested ashomogeneous catalysts for the transesterification of corn oil with methanol. Thestructure of the obtained product was confirmed by 1HNMR analysis. The catalytic results showed that the new Ni(II) complexes can beconsidered as potential candidates for the development of new catalytic systemsfor biodiesel production.

2-(4-ARYL-1H-IMIDAZOL-1-YL)ANILINE COMPOUNDS

The present invention provides compounds that are useful as vaccine adjuvants and/or antitumor agents and methods for producing and using the same. In one particular aspect of the invention, compounds of the invention are of the formula (I) where R1, R2, R3 and Ar1 are those defined herein.

N-1H-Benzimidazol-5-ylbenzenesulfonamide derivatives as potent hPXR agonists

The Human Pregnane X Receptor (hPXR) is a nuclear receptor that regulates the expression of phase I and phase II drug-metabolizing enzymes, as well as that of drug transporters. Because this receptor plays a critical role in protecting tissues from potentially toxic endo- and xenobiotics, highly active agonists could represent novel therapeutic tools in treating several human diseases. Using an in vitro screening reporter system that allow to characterize hPXR activators and a first step of chemical modifications of an original agonist ligand (C2BA-4, 1-(2-chlorophenyl)-N-[1-(1-phenylethyl)-1H-benzimidazol-5-yl]methanesulf onamide), we identified compounds with a N-1H-benzimidazol-5-ylbenzenesulfonamide scaffold as a potent family of hPXR agonists. Further chemical modifications allowed us to identify enhanced activators, notably N-(1-benzyl-1H-benzimidazol-5-yl)-2,3,4,5,6-pentamethylbenzenesulfonamid e (6n) with an EC50 value in the subnanomolar range. Accordingly to their potent EC50, these compounds induced an efficient protection of hPXR against proteolytic digestion by trypsin even at very low ligand concentrations and were able to induce the expression of the main target genes of hPXR, CYP3A4 and CYP2B6, in primary cultures of human hepatocytes.

TNF-α PRODUCTION INHIBITOR

A novel compound of formula (I): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof has a TNF-α production inhibitory activity, it is useful as a method fo

Heterocyclic Ambident Nucleophiles. V. Alkylation of Benzimidazoles

Alkylation of 5-substituted benzimidazole anions with a variety of primary alkyl halides in both protic and aprotic solvents showed only small regioselectivity, with a slight preference for reaction at N 1 for 5-nitro and N 3 for 5-methoxy systems.With 4-substituted benzimidazole anions, alkylation gave more divergent results with the N 1 to N3 regioselectivity varying between 100 : 0 and 29 : 71.These alkylation patterns are interpreted as deriving from an interplay of electrostatic, thermodynamic, steric and associative control factors within the variable SN2 transition state structures involved.In the 4-substituted series, proximity effects, both electrostatic field and steric non-bonded, are clearly dominant.